Colorectal Cancer Immunotherapy: Options and Strategies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Oct 12

PMID 33042104

Citations 195

Authors

Nor Adzimah Johdi

Nur Fazilah Sukor

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients' own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients' own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life.

Citing Articles

Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8 T cell infiltration.

Wang S, Kong L, Wang L, Zhuang Y, Guo C, Zhang Y J Exp Clin Cancer Res. 2025; 44(1):97.

PMID: 40082916 PMC: 11907943. DOI: 10.1186/s13046-025-03358-y.

HAS-CIRCpedia-5280 sponges miR-4712-5p inhibited colon cancer autophagyinduced by human beta-defensin-1.

An S, Cui J, Yang W, Zhang M, Yu H, Lu J J Transl Med. 2025; 23(1):281.

PMID: 40050987 PMC: 11883960. DOI: 10.1186/s12967-024-05860-x.

Identification and functional characterization of m1A-related genes in colorectal cancer: implications for prognosis, immune infiltration, and therapeutic strategies.

Sun L, Huangfu L, Li F, Yan Y, Kong R, Ji K Front Oncol. 2025; 15:1532602.

PMID: 40040720 PMC: 11876182. DOI: 10.3389/fonc.2025.1532602.

L. Extract Inhibits Colorectal Cancer Tumor Growth by Modulating Cell Apoptosis and Autophagy.

Tsai M, Chen C, Chen C, Lee M, Wu L, Hsu Y Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996849 PMC: 11854706. DOI: 10.3390/cimb47020128.

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.

References

Martinez M, Moon E . CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10:128. PMC: 6370640. DOI: 10.3389/fimmu.2019.00128. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Dong Y, Sun Q, Zhang X . PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2016; 8(2):2171-2186. PMC: 5356790. DOI: 10.18632/oncotarget.13895. View

Kershaw M, Wang G, Westwood J, Pachynski R, Tiffany H, Marincola F . Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002; 13(16):1971-80. DOI: 10.1089/10430340260355374. View

Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T . Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. 1994; 23(3):704-6. DOI: 10.1006/geno.1994.1562. View

Gonzalez-Perera I, Gutierrez-Nicolas F, Nazco-Casariego G, Ramos-Diaz R, Hernandez-San Gil R, Perez-Perez J . 5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798). J Oncol Pharm Pract. 2016; 23(5):396-398. DOI: 10.1177/1078155216647202. View

Beer T, Bernstein G, Corman J, Glode L, Hall S, Poll W . Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011; 17(13):4558-67. DOI: 10.1158/1078-0432.CCR-10-3223. View

Eigentler T, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D . Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. 2016; 27(8):1625-32. DOI: 10.1093/annonc/mdw225. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

10.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

11.

Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y . Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers. Mol Ther. 2017; 25(5):1248-1258. PMC: 5417843. DOI: 10.1016/j.ymthe.2017.03.010. View

12.

Marcus A, Gowen B, Thompson T, Iannello A, Ardolino M, Deng W . Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014; 122:91-128. PMC: 4228931. DOI: 10.1016/B978-0-12-800267-4.00003-1. View

13.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

14.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

15.

Scanlan M, Gure A, Jungbluth A, Old L, Chen Y . Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002; 188:22-32. DOI: 10.1034/j.1600-065x.2002.18803.x. View

16.

Dickinson J, CASPARY E, Field E . A common tumour specific antigen. I. Restriction in vivo to malignant neoplastic tissue. Br J Cancer. 1973; 27(2):99-105. PMC: 2008838. DOI: 10.1038/bjc.1973.13. View

17.

Burnet F . The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27. DOI: 10.1159/000386035. View

18.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

19.

Crespo J, Sun H, Welling T, Tian Z, Zou W . T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013; 25(2):214-21. PMC: 3636159. DOI: 10.1016/j.coi.2012.12.003. View

20.

Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T . Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. 2015; 35(1):129-36. View